Aptinyx Inc. (APTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
APTX Stock Price Chart Interactive Chart >
APTX Price/Volume Stats
| Current price | $0.12 | 52-week high | $2.87 |
| Prev. close | $0.13 | 52-week low | $0.12 |
| Day low | $0.12 | Volume | 5,780,100 |
| Day high | $0.13 | Avg. volume | 3,259,563 |
| 50-day MA | $0.35 | Dividend yield | N/A |
| 200-day MA | $0.39 | Market Cap | 8.45M |
Aptinyx Inc. (APTX) Company Bio
Aptinyx Inc. develops therapeutics for neurological disorders. The company is focused on the development of drugs that interact with the NMDA receptor, and the company says it will use the funds to advance drugs for chronic pain, post-traumatic stress disorder (PTSD) and cognitive impairment in Parkinson’s disease. The company was founded in 2015 and is based in Evantson, Illinois.
Latest APTX News From Around the Web
Below are the latest news stories about APTINYX INC that investors may wish to consider to help them evaluate APTX as an investment opportunity.
Bicycle (BCYC) up on Collaboration With Novartis for ConjugatesBicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news. |
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes DrugVertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs. |
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock UpPharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to start off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Friday! |
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept BiosimilarCOYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302. |
APTX Price Returns
| 1-mo | -38.78% |
| 3-mo | -57.94% |
| 6-mo | -67.40% |
| 1-year | -94.71% |
| 3-year | -94.44% |
| 5-year | N/A |
| YTD | -57.94% |
| 2022 | -89.31% |
| 2021 | -22.83% |
| 2020 | 1.17% |
| 2019 | -79.32% |
| 2018 | N/A |
Continue Researching APTX
Want to see what other sources are saying about Aptinyx Inc's financials and stock price? Try the links below:Aptinyx Inc (APTX) Stock Price | Nasdaq
Aptinyx Inc (APTX) Stock Quote, History and News - Yahoo Finance
Aptinyx Inc (APTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...